212 related articles for article (PubMed ID: 29712773)
1. Chronic Lymphocytic Leukemia-Derived IL-10 Suppresses Antitumor Immunity.
Alhakeem SS; McKenna MK; Oben KZ; Noothi SK; Rivas JR; Hildebrandt GC; Fleischman RA; Rangnekar VM; Muthusamy N; Bondada S
J Immunol; 2018 Jun; 200(12):4180-4189. PubMed ID: 29712773
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-10 suppression enhances T-cell antitumor immunity and responses to checkpoint blockade in chronic lymphocytic leukemia.
Rivas JR; Liu Y; Alhakeem SS; Eckenrode JM; Marti F; Collard JP; Zhang Y; Shaaban KA; Muthusamy N; Hildebrandt GC; Fleischman RA; Chen L; Thorson JS; Leggas M; Bondada S
Leukemia; 2021 Nov; 35(11):3188-3200. PubMed ID: 33731852
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model.
McClanahan F; Riches JC; Miller S; Day WP; Kotsiou E; Neuberg D; Croce CM; Capasso M; Gribben JG
Blood; 2015 Jul; 126(2):212-21. PubMed ID: 25979947
[TBL] [Abstract][Full Text] [Related]
4. Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function.
DiLillo DJ; Weinberg JB; Yoshizaki A; Horikawa M; Bryant JM; Iwata Y; Matsushita T; Matta KM; Chen Y; Venturi GM; Russo G; Gockerman JP; Moore JO; Diehl LF; Volkheimer AD; Friedman DR; Lanasa MC; Hall RP; Tedder TF
Leukemia; 2013 Jan; 27(1):170-82. PubMed ID: 22713648
[TBL] [Abstract][Full Text] [Related]
5. CD4+ T cells sustain aggressive chronic lymphocytic leukemia in Eμ-TCL1 mice through a CD40L-independent mechanism.
Grioni M; Brevi A; Cattaneo E; Rovida A; Bordini J; Bertilaccio MTS; Ponzoni M; Casorati G; Dellabona P; Ghia P; Bellone M; Calcinotto A
Blood Adv; 2021 Jul; 5(14):2817-2828. PubMed ID: 34269799
[TBL] [Abstract][Full Text] [Related]
6. HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model.
Maharaj K; Powers JJ; Mediavilla-Varela M; Achille A; Gamal W; Quayle S; Jones SS; Sahakian E; Pinilla-Ibarz J
Front Immunol; 2020; 11():590072. PubMed ID: 33329575
[TBL] [Abstract][Full Text] [Related]
7. EOMES and IL-10 regulate antitumor activity of T regulatory type 1 CD4
Roessner PM; Llaó Cid L; Lupar E; Roider T; Bordas M; Schifflers C; Arseni L; Gaupel AC; Kilpert F; Krötschel M; Arnold SJ; Sellner L; Colomer D; Stilgenbauer S; Dietrich S; Lichter P; Izcue A; Seiffert M
Leukemia; 2021 Aug; 35(8):2311-2324. PubMed ID: 33526861
[TBL] [Abstract][Full Text] [Related]
8. Leukemic cell-secreted interleukin-9 suppresses cytotoxic T cell-mediated killing in chronic lymphocytic leukemia.
Boncompagni G; Tatangelo V; Lopresti L; Ulivieri C; Capitani N; Tangredi C; Finetti F; Marotta G; Frezzato F; Visentin A; Ciofini S; Gozzetti A; Bocchia M; Calzada-Fraile D; Martin Cofreces NB; Trentin L; Patrussi L; Baldari CT
Cell Death Dis; 2024 Feb; 15(2):144. PubMed ID: 38360867
[TBL] [Abstract][Full Text] [Related]
9. Two types of BCR interactions are positively selected during leukemia development in the Eμ-TCL1 transgenic mouse model of CLL.
Iacovelli S; Hug E; Bennardo S; Duehren-von Minden M; Gobessi S; Rinaldi A; Suljagic M; Bilbao D; Bolasco G; Eckl-Dorna J; Niederberger V; Autore F; Sica S; Laurenti L; Wang H; Cornall RJ; Clarke SH; Croce CM; Bertoni F; Jumaa H; Efremov DG
Blood; 2015 Mar; 125(10):1578-88. PubMed ID: 25564405
[TBL] [Abstract][Full Text] [Related]
10. The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the Eμ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling.
Suljagic M; Longo PG; Bennardo S; Perlas E; Leone G; Laurenti L; Efremov DG
Blood; 2010 Dec; 116(23):4894-905. PubMed ID: 20716772
[TBL] [Abstract][Full Text] [Related]
11. Interleukin-27 potentiates CD8+ T-cell-mediated antitumor immunity in chronic lymphocytic leukemia.
Pagano G; Botana IF; Wierz M; Roessner PM; Ioannou N; Zhou X; Al-Hity G; Borne C; Gargiulo E; Gonder S; Qu B; Stamatopoulos B; Ramsay AG; Seiffert M; Largeot A; Moussay E; Paggetti J
Haematologica; 2023 Nov; 108(11):3011-3024. PubMed ID: 37345470
[TBL] [Abstract][Full Text] [Related]
12. Absence of caveolin-1 leads to delayed development of chronic lymphocytic leukemia in Eμ-TCL1 mouse model.
Shukla A; Cutucache CE; Sutton GL; Pitner MA; Rai K; Rai S; Opavsky R; Swanson PC; Joshi SS
Exp Hematol; 2016 Jan; 44(1):30-7.e1. PubMed ID: 26435347
[TBL] [Abstract][Full Text] [Related]
13. PTPROt-mediated regulation of p53/Foxm1 suppresses leukemic phenotype in a CLL mouse model.
Motiwala T; Kutay H; Zanesi N; Frissora FW; Mo X; Muthusamy N; Jacob ST
Leukemia; 2015 Jun; 29(6):1350-9. PubMed ID: 25482129
[TBL] [Abstract][Full Text] [Related]
14. E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction.
Gorgun G; Ramsay AG; Holderried TA; Zahrieh D; Le Dieu R; Liu F; Quackenbush J; Croce CM; Gribben JG
Proc Natl Acad Sci U S A; 2009 Apr; 106(15):6250-5. PubMed ID: 19332800
[TBL] [Abstract][Full Text] [Related]
15. Exploiting B-cell Receptor Stereotypy to Design Tailored Immunotherapy in Chronic Lymphocytic Leukemia.
Rovida A; Maccalli C; Scarfò L; Dellabona P; Stamatopoulos K; Ghia P
Clin Cancer Res; 2021 Feb; 27(3):729-739. PubMed ID: 33051305
[TBL] [Abstract][Full Text] [Related]
16. Expanded CD8+ T cells of murine and human CLL are driven into a senescent KLRG1+ effector memory phenotype.
Göthert JR; Eisele L; Klein-Hitpass L; Weber S; Zesewitz ML; Sellmann L; Röth A; Pircher H; Dührsen U; Dürig J
Cancer Immunol Immunother; 2013 Nov; 62(11):1697-1709. PubMed ID: 24022692
[TBL] [Abstract][Full Text] [Related]
17. Accelerated progression of chronic lymphocytic leukemia in Eμ-TCL1 mice expressing catalytically inactive RAG1.
Nganga VK; Palmer VL; Naushad H; Kassmeier MD; Anderson DK; Perry GA; Schabla NM; Swanson PC
Blood; 2013 May; 121(19):3855-66, S1-16. PubMed ID: 23502221
[TBL] [Abstract][Full Text] [Related]
18. Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice.
Zanesi N; Aqeilan R; Drusco A; Kaou M; Sevignani C; Costinean S; Bortesi L; La Rocca G; Koldovsky P; Volinia S; Mancini R; Calin G; Scott CP; Pekarsky Y; Croce CM
Cancer Res; 2006 Jan; 66(2):915-20. PubMed ID: 16424025
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of TCL1 activates the endoplasmic reticulum stress response: a novel mechanism of leukemic progression in mice.
Kriss CL; Pinilla-Ibarz JA; Mailloux AW; Powers JJ; Tang CH; Kang CW; Zanesi N; Epling-Burnette PK; Sotomayor EM; Croce CM; Del Valle JR; Hu CC
Blood; 2012 Aug; 120(5):1027-38. PubMed ID: 22692508
[TBL] [Abstract][Full Text] [Related]
20. Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor.
Reinart N; Nguyen PH; Boucas J; Rosen N; Kvasnicka HM; Heukamp L; Rudolph C; Ristovska V; Velmans T; Mueller C; Reiners KS; von Strandmann EP; Krause G; Montesinos-Rongen M; Schlegelberger B; Herling M; Hallek M; Fingerle-Rowson G
Blood; 2013 Jan; 121(5):812-21. PubMed ID: 23118218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
